The Estée Lauder Companies Launches 2023 Breast Cancer Campaign: Beautifully United to Help End Breast Cancer
29.9.2023 14:00:00 EEST | Business Wire | Press release
For more than 30 years, The Estée Lauder Companies’ Breast Cancer Campaign (The Campaign) has been dedicated to advancing the possibility of a breast cancer-free world for all. This October, The Estée Lauder Companies (ELC) honors Breast Cancer Awareness Month by launching The Campaign in support of the global breast cancer community.
As ELC’s largest corporate social impact program, The Campaign continues to inspire purpose-driven action and is a cornerstone of the company’s social investments in women’s advancement, health and education. Through The Campaign, ELC has also been a longstanding supporter of women in science, research and medicine – funding numerous grants and programs around the world and accelerating opportunities for women in STEM.
The Campaign was founded by Evelyn H. Lauder in 1992 with the launch of the iconic Pink Ribbon. At a time when breast cancer wasn’t spoken about openly, Evelyn and ELC saw an opportunity to bring awareness to the disease and address stigmas in women’s health – inspiring a global movement around The Campaign’s mission to help create a breast cancer-free world for all.
Together, The Estée Lauder Companies’ Breast Cancer Campaign and The Estée Lauder Companies Charitable Foundation (ELCCF) have funded more than $118 million globally for life saving research, education, and medical services, with more than $93 million funding medical research through the Breast Cancer Research Foundation (BCRF). BCRF, also founded by Evelyn Lauder in 1993, is The Campaign’s leading non-profit partner, dedicated to advancing the world’s most promising research to eradicate breast cancer.
In honor of The Campaign’s 30th Anniversary in 2022, ELCCF made a commitment to donate $15 million over five years to BCRF to fund groundbreaking research that will further the goal of reducing breast cancer disparities and improving outcomes. This comprehensive study of the intersection of social determinants of health, comorbidities and the biology of breast cancer in Black women has the potential to significantly impact breast cancer disparities globally. A diverse steering committee, as well as sub-committees, comprised of BCRF experts in disparities from acclaimed academic and medical institutions from across the country have established initial targets critical to identifying the roots of health equity and disparities in breast cancer outcomes. Information from thousands of patients will build this vital data-generating project and is the first step in this multi-year initiative.
This year, The Campaign will:
- Support 60+ organizations worldwide aligned to the diverse needs of local communities
- Honor the 20th Anniversary of The Breast Cancer Campaign in China, including the illumination of No.1 Wai Tan Yuan, Shanghai
- Address disparities that exist across the entire breast cancer landscape
- Fund medical research and fellowships worldwide
- Fund medical resources and services including access to mammograms/screenings for vulnerable groups with limited access to healthcare
- Provide support, therapy and counseling programs
- Host and convene events to advance education on breast health with key opinion leaders and experts - encouraging stakeholders everywhere to become breast health advocates
- Issue an Instagram call-to-action (@esteelaudercompanies) on October 1 to engage audiences and raise funds for BCRF using #TimeToEndBreastCancer
- Engage ELC’s brands: AERIN Beauty, Aveda, Bobbi Brown Cosmetics, Bumble and bumble, Clinique, Darphin, Dr.Jart+, Editions de Parfums Frédéric Malle, Estée Lauder, Jo Malone London, KILIAN PARIS, La Mer, Lab Series, Origins, Smashbox, TOM FORD BEAUTY and Too Faced – with each donating to BCRF and/or local cancer-focused organizations around the world through product sales or flat donations (brand participation varying by market)
- Illuminate buildings, monuments and landmarks around the world in pink to raise awareness, including Empire State Building, New York City; Eiffel Tower, Paris; Burj Al Arab, United Arab Emirates, among others
"ELC has an unwavering commitment to social impact, with The Breast Cancer Campaign at the forefront of these efforts. I am incredibly proud of the progress we have made ever since my mother, Evelyn Lauder, started The Campaign more than 30 years ago," said William P. Lauder, Executive Chairman, The Estée Lauder Companies Inc. "Our passionate employees, consumers and partners have united to advance possibilities for those affected by this disease. Together, we will continue powering progress, until we realize my mother’s vision of a breast cancer-free world for all."
The call to end breast cancer is more urgent than ever as breast cancer is the most commonly diagnosed cancer worldwide. As long as breast cancer is a life-threatening disease, ELC’s commitment remains unwavering.
To learn more, visit: ELCompanies.com/BreastCancerCampaign and @esteelaudercompanies on Instagram.
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
ELC-C
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230929689607/en/
Contact information
Erin Cohen
The Estée Lauder Companies
ercohen@estee.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SMBC and Toshiba Jointly Develop New Equity Indices Using Advanced Quantum-Driven Technologies28.5.2026 04:00:00 EEST | Press release
Sumitomo Mitsui Banking Corporation (“SMBC”) and Toshiba Corporation (“Toshiba”) today announced the joint development of the SMBC/TOSHIBA Quantum Driven Diversified Japan Equity Index and the SMBC/TOSHIBA Quantum Driven Diversified U.S. Equity Index, new equity indices realized with advanced quantum-driven technologies. Collectively, the indices are referred to as “SMBC/TOSHIBA Quantum Diversified” (the “Indices”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519448161/en/ Toshiba’s Simulated Bifurcation Machine 1. Background and Objectives Equity investment is central to asset management, but it also carries the ever-present risk of abrupt and substantial market fluctuations driven by geopolitical developments, changes in economic policy, and other external factors. In uncertain markets, investors are constantly seeking innovations in risk diversification that can protect their assets from unexpected market shocks. SM
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 202628.5.2026 00:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago.The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without TEVIMBRA® (tislelizumab), compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA). Dr. Sun Young Rha, Professor of Medical Oncology at the Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, senior author of the NEJM manuscript and first author of the ASCO abstract, said: “Results from the HERIZON-GEA-01 published in The New England Journal of Medicine and presented in an oral presentation at ASCO provide ne
Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards27.5.2026 18:22:00 EEST | Press release
The Stallergenes Greer Foundation, dedicated to advancing allergy research, fostering innovation and addressing environmental factors which impact allergies, is delighted to announce the recipients of the 2025 edition of its prestigious Science Awards for Allergy. Building on the success of the previous edition, this year’s awards recognise outstanding contributions to allergy research and patient engagement and allocate a total of €100,000 to support these initiatives. Four researchers have been selected by the Board as award recipients, each receiving €25,000 across two categories: Innovation In Treatment Awards Assoc. Professor Alexander Eggel, PhD, Department for Biomedical Research, University of Bern, and Department of Rheumatology and Immunology, University Hospital Bern, Switzerland, recognised for his research: “Improving diagnostic and therapeutic options for allergic patients”; Dr Janice A. Layhadi, PhD, Research Associate, National Heart and Lung Institute, Imperial College
Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates27.5.2026 17:00:00 EEST | Press release
Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features. The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing. The Market Shift: Financing as a Growth Lever for B2B Tech Companies The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting. Capchase replaces those bottlenecks with financing tech embedded directly into sales tools such as Salesforce, enabling 97% of lending applications to be vetted and
ClickHouse Tops $250M ARR and 4,000 Customers, Launches Claude-Powered Agents at Open House 202627.5.2026 16:00:00 EEST | Press release
ClickHouse today opened Open House 2026, its second annual user conference, with a set of announcements that mark one of the company's most active quarters since founding. ClickHouse’s serverless cloud offering has crossed over $250 million in annual run-rate revenue — more than triple a year ago — and added more than 1,000 net new customers since January, bringing its total to 4,000. To meet the demands of AI-era workloads, the company also launched ClickHouse Agents, a fully managed agentic analytics service powered by Anthropic's Claude; published CostBench, an open benchmark comparing the major cloud data warehouses on cost-performance; and introduced House Mates, its first formal partner program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527813115/en/ ClickHouse Co-Founders (left to right): Yury Izrailevsky, Aaron Katz, Alexey Milovidov Growth When ClickHouse closed its $400 million Series D in January 2026, it
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
